Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
- Author
- KAPPOS, Ludwig1 ; LI, David2 ; HAUSER, Stephen L9 ; CALABRESI, Peter A3 ; O'CONNOR, Paul4 ; BAR-OR, Amit5 ; BARKHO, Frederik6 ; MING YIN7 ; LEPPERT, David8 ; GLANZMAN, Robert8 ; TINBERGEN, Jeroen8
[1] University Hospital, Basel, Switzerland
[2] University of British Columbia, Vancouver, BC, Canada
[3] Johns Hopkins University, Baltimore, MD, United States
[4] University of Toronto, Toronto, ON, Canada
[5] McGill University, Montreal, QC, Canada
[6] VU University Medical Centre, Amsterdam, Netherlands
[7] Genentech Inc, South San Francisco, CA, United States
[8] F Hoffmann-La Roche Ltd, Basel, Switzerland
[9] University of California San Francisco, San Francisco, CA, United States - Source
Lancet (British edition). 2011, Vol 378, Num 9805, pp 1779-1787, 9 p ; ref : 30 ref
- CODEN
- LANCAO
- ISSN
- 0140-6736
- Scientific domain
- General medicine general surgery
- Publisher
- Elsevier, Kidlington
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Keyword (fr)
- Antirhumatismal Essai clinique Etude multicentrique Immunomodulateur Médecine Ocrélizumab Phase Placebo Récidive Sclérose en plaques Essai randomisé contrôlé Anticorps monoclonal Maladie inflammatoire Pathologie du système nerveux central Pathologie du système nerveux
- Keyword (en)
- Antirheumatic agent Clinical trial Multicenter study Immunomodulator Medicine Ocrelizumab Phase Placebo Relapse Multiple sclerosis Randomized controlled trial Monoclonal antibody Inflammatory disease Central nervous system disease Nervous system diseases
- Keyword (es)
- Antireumático Ensayo clínico Estudio multicéntrico Inmunomodulador Medicina Ocrelizumab Fase Placebo Recaida Esclerosis en placa Ensayo aleatorio controlado Anticuerpo monoclonal Enfermedad inflamatoria Sistema nervosio central patología Sistema nervioso patología
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B17 Neurology / 002B17F Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis
- Discipline
- Generalities in medical sciences Neurology
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 24781228
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1016/S0140-6736(11)61649-8 
https://dx.doi.org/10.1016/S0140-6736(11)61649-8
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(11)61649-8\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:115:\"Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:3:\"378\";s:8:\"\u0000*\u0000issue\";s:4:\"9805\";s:8:\"\u0000*\u0000spage\";s:4:\"1779\";s:8:\"\u0000*\u0000epage\";s:4:\"1787\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"KAPPOS\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Ludwig\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:9:\"LI, David\";i:1;s:17:\"HAUSER, Stephen L\";i:2;s:18:\"CALABRESI, Peter A\";i:3;s:14:\"O'CONNOR, Paul\";i:4;s:12:\"BAR-OR, Amit\";i:5;s:16:\"BARKHO, Frederik\";i:6;s:8:\"MING YIN\";i:7;s:14:\"LEPPERT, David\";i:8;s:16:\"GLANZMAN, Robert\";i:9;s:17:\"TINBERGEN, Jeroen\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:115:\"Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(11)61649-8\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:115:\"Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:3:\"378\";s:8:\"\u0000*\u0000issue\";s:4:\"9805\";s:8:\"\u0000*\u0000spage\";s:4:\"1779\";s:8:\"\u0000*\u0000epage\";s:4:\"1787\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"KAPPOS\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Ludwig\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:9:\"LI, David\";i:1;s:17:\"HAUSER, Stephen L\";i:2;s:18:\"CALABRESI, Peter A\";i:3;s:14:\"O'CONNOR, Paul\";i:4;s:12:\"BAR-OR, Amit\";i:5;s:16:\"BARKHO, Frederik\";i:6;s:8:\"MING YIN\";i:7;s:14:\"LEPPERT, David\";i:8;s:16:\"GLANZMAN, Robert\";i:9;s:17:\"TINBERGEN, Jeroen\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:115:\"Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(11)61649-8\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(11)61649-8\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:115:\"Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:3:\"378\";s:8:\"\u0000*\u0000issue\";s:4:\"9805\";s:8:\"\u0000*\u0000spage\";s:4:\"1779\";s:8:\"\u0000*\u0000epage\";s:4:\"1787\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"KAPPOS\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Ludwig\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:9:\"LI, David\";i:1;s:17:\"HAUSER, Stephen L\";i:2;s:18:\"CALABRESI, Peter A\";i:3;s:14:\"O'CONNOR, Paul\";i:4;s:12:\"BAR-OR, Amit\";i:5;s:16:\"BARKHO, Frederik\";i:6;s:8:\"MING YIN\";i:7;s:14:\"LEPPERT, David\";i:8;s:16:\"GLANZMAN, Robert\";i:9;s:17:\"TINBERGEN, Jeroen\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:115:\"Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(11)61649-8\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:115:\"Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:3:\"378\";s:8:\"\u0000*\u0000issue\";s:4:\"9805\";s:8:\"\u0000*\u0000spage\";s:4:\"1779\";s:8:\"\u0000*\u0000epage\";s:4:\"1787\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"KAPPOS\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Ludwig\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:9:\"LI, David\";i:1;s:17:\"HAUSER, Stephen L\";i:2;s:18:\"CALABRESI, Peter A\";i:3;s:14:\"O'CONNOR, Paul\";i:4;s:12:\"BAR-OR, Amit\";i:5;s:16:\"BARKHO, Frederik\";i:6;s:8:\"MING YIN\";i:7;s:14:\"LEPPERT, David\";i:8;s:16:\"GLANZMAN, Robert\";i:9;s:17:\"TINBERGEN, Jeroen\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:115:\"Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(11)61649-8\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:115:\"Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:3:\"378\";s:8:\"\u0000*\u0000issue\";s:4:\"9805\";s:8:\"\u0000*\u0000spage\";s:4:\"1779\";s:8:\"\u0000*\u0000epage\";s:4:\"1787\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"KAPPOS\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Ludwig\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:9:\"LI, David\";i:1;s:17:\"HAUSER, Stephen L\";i:2;s:18:\"CALABRESI, Peter A\";i:3;s:14:\"O'CONNOR, Paul\";i:4;s:12:\"BAR-OR, Amit\";i:5;s:16:\"BARKHO, Frederik\";i:6;s:8:\"MING YIN\";i:7;s:14:\"LEPPERT, David\";i:8;s:16:\"GLANZMAN, Robert\";i:9;s:17:\"TINBERGEN, Jeroen\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:115:\"Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
